Johns Hopkins recently announced its National COVID-19 Convalescent Plasma Project, a clinical trial investigating the role of convalescent plasma in the potential treatment of COVID-19. Led by Johns Hopkins, participating researchers include Dr. Shmuel Shoham, associate professor of medicine and Dr. David Sullivan, professor of molecular microbiology and immunology at the Hopkins Malaria Research. Of note for this study, the team focuses on the effects of convalescent plasma for two different instances: early infection and post-exposure. The U.S. FDA recently issued an emergency use authorization (EUA) making it more difficult to conduct clinical studies. Some believed that this decision by the FDA was influenced by political forces.
The early infection study seeks 600 patients who have been infected with COVID-19 but are not hospitalized. The outpatient study is a randomized clinical trial; half of the participants are infused with high-antibody titer plasma while the other half receive plasma without antibodies.
The News-Letter interview
The Johns Hopkins News -Letter recently shared an interview with the investigators involved with this important study. With the goal of understanding if plasma infusion can prevent progression of COVID-19 to a state that requires hospitalization.
Follow the link to read Medha Kallem’s interview with the Johns Hopkins investigators involved with the National COVID-19 Convalescent Plasma Project.
Dr. Shmuel Shoham, MD, associate professor of medicine
Dr. David Sullivan, MD, professor of molecular microbiology and immunology at the Hopkins Malaria Research.
Call to Action: Check out Johns Hopkins News-Letter.